1 Differential expression analyses on aortic tissue reveal novel genes and pathways associated

2 with abdominal aortic aneurysm onset and progression

- 3 Gerard Temprano-Sagrera MSc (gtemprano@santpau.cat)¹, Begoña Soto MD PhD
- 4 (bsoto@santpau.cat)^{1,2}, Jaume Dilmé MD PhD (jdilme@santpau.cat)^{1,2,3}, Olga Peypoch MD
- 5 (opeypoch@santpau.cat)^{1,2}, Laura Calsina Juscafresa MD PhD (lcalsina@psmar.cat)^{4,5}, David
- 6 Davtian PhD⁶ (2400580@dundee.ac.uk), Lluís Nieto MD (llnietofernandez@gmail.com)⁴,
- 7 Andrew Brown PhD (a.z.t.brown@dundee.ac.uk)⁶, José Román Escudero MD
- 8 (jescuderor@santpau.cat)^{1,2}, Ana Viñuela PhD# (ana.vinuela@newcastle.ac.uk)⁷, Mercedes
- 9 Camacho PhD# (mcamacho@santpau.cat)¹, Maria Sabater-Lleal PhD#
- 10 (msabater@santpau.cat)^{1,8,9}
- 11
- 12 #These authors equally contributed as senior authors.
- 13
- 14 Affiliations:
- 15
- Unit of genomics of Complex Diseases, Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79,
 08041 Barcelona, Spain
- 18 2. Servei d'Angiologia i Cirurgia Vascular i Endovascular, Hospital de la Santa Creu i Sant Pau, Sant Antoni
- 19 Maria Claret 167, 08025 Barcelona, Spain
- 20 3. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERECV), Madrid,
- 21 Spain
- 4. Department of Vascular and Endovascular Surgery, Hospital del Mar, Passeig Marítim 25-29, 08003,
 Barcelona, Spain
- 24 5. Department of Medicine and Surgery, Universitat Pompeu Fabra, Barcelona, Spain
- 25 6. Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee,
- 26 Dundee, DD1 9SY, United Kingdom.
- 7. Biosciences Institute, Faculty of Medical Sciences, University of Newcastle, Newcastle upon Tyne, NE1
 4EP, United Kingdom
- 29 8. Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
- 30 9. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- 31
- 3233 Corresponding author:
- 33 Corresponding autho
- 35 Maria Sabater-Lleal, PhD
- 36 Genomics of Complex Disease Unit, Institut de Recerca Sant Pau (IR SANT PAU)
- 37 St Quintí 77-79, 08041, Barcelona, Spain
- 38 Phone +34932919000; Email: msabater@santpau.cat
- 39

40 ABSTRACT

41 Background:

42 Abdominal aortic aneurysms (AAA) are focal dilatations of the abdominal aorta. They are 43 normally asymptomatic and progressively expand, increasing their risk of rupture. Rupture of 44 an AAA is associated with high mortality rates, but the mechanisms underlying the initiation, 45 expansion and rupture of AAA are not yet fully understood. This study aims to characterize and 46 identify new genes associated with the pathophysiology of AAA through differential expression 47 analyses between dilated and non-dilated aortic tissue samples, and between AAA of different 48 diameters. Our study used RNA-seq data on 140 samples, becoming the largest RNA-seq 49 dataset for differential expression studies of AAA.

50 <u>Results</u>:

51 We identified 7,454 differentially expressed genes (DEGs) between AAA and controls, 2,851 of which were new compared to previous microarray studies. Notably, a novel cluster on 52 53 adenosine triphosphate synthesis regulation emerged as strongly associated with AAA. 54 Additionally, exploring AAA of different diameters identified eight genes (EXTL3, ZFR, DUSP8, 55 DISP1, USP33, VPS37C, ZNF784, RFX1) that overlapped with the DEGs between AAA and 56 controls, implying roles in both disease onset and progression. Seven genes (SPP1, FHL1, GNAS, 57 MORF4L2, HMGN1, ARL1, RNASE4) with differential splicing patterns were also DEGs between 58 AAA and controls, suggesting that splicing differences contribute to the observed expression 59 changes and the disease development.

60 <u>Conclusions</u>:

This study identified new genes and pathways associated with AAA onset and progression and
validated previous relevant roles of inflammation and intracellular calcium regulation. These

- 63 findings provide insights into the complex mechanisms underlying AAA and indicate potential
- 64 targets to limit AAA progression and mortality risk.
- **KEYWORDS**: Abdominal aortic aneurysm, RNAseq, transcriptomics, differential expression,
- 66 ischemic time, alternative splicing, allelic specific expression.

84 BACKGROUND:

85 Abdominal aortic aneurysms (AAA) are characterized by a local dilation of the infrarenal 86 abdominal aorta to about 1.5 times the normal adjacent aortic diameter or more than 3 cm in 87 maximum diameter[1]. AAA is accompanied by chronic inflammation, apoptosis of vascular 88 smooth muscle cells and neovascularization[2,3]. Additionally, extracellular matrix degradation, 89 microcalcification, and oxidative stress contribute to the degeneration of the aorta[1,2]. The 90 disease is progressive, and most aneurysms develop without causing symptoms[1]. However, in 91 the event of AAA rupture, mortality rates can reach 80 %[4]. The only effective treatment 92 currently available for AAA is aortic tissue repair, either through open surgery or endovascular 93 repair[1,5].

Some risk factors are known for developing AAA, including age, male sex, smoking, and family history of AAA[1]. Smoking, in addition, is also known to increase the risk of rupture[6]. Additionally, recent genomic studies have revealed 121 loci associated with risk of developing AAA, contributing to the knowledge of the possible pathways leading to this disease[7]. However, there is still an insufficient understanding of the clear mechanisms that underlie the initiation, propagation, and rupture of AAA.

100 The study of gene expression, known as transcriptomics, is a valuable tool for understanding 101 human disease and revealing new therapeutic targets [8,9]. Several studies have been 102 performed to study the differentially expressed genes (DEGs) between dilated aortic tissue and 103 non-dilated control aorta using microarray technology, detecting DEGs especially associated 104 with the immune and inflammatory responses, extracellular matrix remodeling and 105 angiogenesis[10-15]. In the present study, we performed RNA sequencing (RNAseq) of the 106 complete transcriptome in 140 abdominal aortic tissue samples (96 dilated aortas and 44 107 control aortas from deceased donors) from the Triple A Barcelona Study (TABS) cohort, to 108 identify new DEGs and pathways associated with the pathophysiology of AAA initiation and

- 109 progression, allowing for a more comprehensive analysis of the transcriptome and becoming
- 110 the largest RNAseq dataset for AAA tissue. Additionally, we aimed to investigate the differences
- in alternative splicing patterns in the context of AAA, and the role of genetic variants in gene
- 112 expression in AAA tissue. The study design is described in Figure 1.
- 113 **RESULTS**:
- 114 <u>Participants characteristics:</u>
- 115 **Table 1** shows the participants demographic and clinical data. Aortic tissue samples from 96
- 116 AAA patients and 44 controls from the TABS cohort were used for RNAseq analysis.

Table 1: Characteristics of study participants

	Controls	AAA	Durshus	Missing
	(N = 44)	(N = 96)	P-value	values (%)
Age (Years)	61.66 (21-82)	70.38 (53-87)	0.0006	0 (0)
Sex (Male)	21 (47.73)	92 (95.83)	1.00E-10	0 (0)
Smoking (Current)	8 (21.62)	27 (32.14)	0.3378	19 (13.57)
Smoking (Past)	3 (8.11)	42 (50)	2.81E-05	19 (13.57)
Aortic Diameter (mm)	NA	65.57 (38-100.12)	-	0 (0)
Hypertension (Yes)	15 (40.54)	54 (64.29)	0.0256	19 (13.57)
Dyslipidemia (Yes)	10 (27.03)	46 (54.76)	0.0087	19 (13.57)
Diabetes mellitus (Yes)	5 (13.51)	12 (14.29)	1	19 (13.57)
Peripheral arterial disease (Yes)	NA	23 (27.71)	-	57 (59.38)
Other aneurysms (Yes)	NA	25 (29.76)	-	12 (12.5)
Cerebrovascular Disease (Yes)	3 (8.11)	36 (43.9)	0.0003	21 (15)
Cardiovascular Disease (Yes)	1 (3.34)	16 (19.05)	0.0846	27 (19.29)
Chronic obstructive pulmonary disease (Yes)	1 (2.7)	15 (17.86)	0.0481	19 (13.57)

Chronic kidney disease (Yes)	2 (5.4)	17 (20.24)	0.0726	19 (13.57)
Continuous variables are presented	as mean (range),	and categorical variables are	presented as	
%. Two-sample t-tests and chi-squ	ared tests were u	used to compare the means o	f continuous	
phenotypes and the distribution of	categorical pher	notypes, between AAA and co	ntrol groups,	
respectively. Missing values were ex	cluded from the	calculations of each variable.	Hypertension	
was defined based on clinical histor	ry and the use of	antihypertensive medication.	Dyslipidemia	
was diagnosed through clinical hi	story and the u	se of hypolipidemic medicati	on. Diabetes	
mellitus was identified by clinica	al history and t	he use of insulin or oral h	nypoglycemic	
medications, without differentiation	n between type 1	l or type 2. Peripheral arterial	disease was	
assessed based on clinical symptor	ms and clinical h	istory. Other aneurysms inclu	ded thoracic	
and visceral aortic aneurysms, ilia	ic artery aneurys	sms, and popliteal artery ane	urysms, and	
were diagnosed using computed t	omography or u	ltrasound. Cerebrovascular d	iseases were	
determined by a history of transie	nt ischemic attac	ck or stroke. Cardiovascular d	iseases were	
assessed by history of acute myocar	rdial infarction o	r angina pectoris, or admission	with clinical	
symptoms, electrocardiogram cho	anges, or a po	sitive enzymatic curve diag	nosed by a	
cardiologist. Chronic obstructive p	ulmonary disease	e was identified based on cli	nical history.	
Chronic kidney disease was assessed	d by clinical histo	ry.		

117 We examined demographic and clinical variables between AAA and controls to determine whether these might influence our expression levels differences. We found significant 118 119 differences in sex (Additional file 1: Figure S1A), age (Additional file 1: Figure S1B), smoking 120 status, and the prevalence of hypertension, dyslipidemia, cerebrovascular disease, and chronic 121 obstructive pulmonary disease between AAA patients and controls. In relation to smoking 122 status (N = 122), which is a known risk factor for AAA development and rupture, 70.3 % of 123 controls were never smokers, compared to 17.86 % of AAA patients. Among current and past 124 smokers, there were also differences, with 50 % of former smokers and 32.14 % of current 125 smokers in AAA, compared to only 8.11 % and 21.62 % respectively, in the controls (Additional

126 **file 1: Figure S3C**). We adjusted our regression analyses for age and sex, acknowledging their

- 127 potential influence on expression level differences.
- 128 <u>Differential expression analyses between AAA and controls</u>:

129 The analysis of differential expression between aortic samples from 96 AAA patients and 44 130 controls revealed 7,454 genes displaying significant differences in expression (adjusted p-value 131 < 0.05) (Additional file 1: Figure S2A and Additional file 2: Table S1). This number exceeds by 132 26.57 % the previous DEGs identified in comparable analyses using microarray 133 technologies[10–15]. Using GO and KEGG enrichment analyses, we found a total of 1,152 and 134 89 enriched terms, respectively (Additional file 1: Figure S3A and Figure S4A). The complete 135 results of the enriched terms for GO and KEGG are shown in Additional files 3 and 4: Tables S2 136 and S3. To better characterize the biological processes associated with the DEGs in the 137 enrichment analysis, we performed a cluster analysis of GO pathways. We found that most of 138 the DEGs were associated with the immune system: regulation of mononuclear cell 139 proliferation, leukocyte chemotaxis, regulation of adaptive immune response based on somatic 140 recombination of immune receptors built from immunoglobulin superfamily domains, mast cell 141 degranulation, major histocompatibility complex (MHC) class II protein complex, positive 142 regulation of T cell activation, and CD4-positive alpha-beta T cell differentiation (Figure 2A). 143 Other represented metabolic pathways were related to sequestering of calcium ion, regulation 144 of actin filament length and adenosine triphosphate (ATP) synthesis coupled electron transport 145 (Figure 2A). While these analyses corroborated previous associations with inflammatory, actin 146 filament regulation and intracellular calcium regulation processes, the ATP synthesis regulation 147 pathway was a new differential expressed pathway in AAA tissue.

148 Control aortic samples from deceased organ donors have been used by us and others [10– 149 13,15]. To account for differences in gene expression between AAA and control tissue that 150 could be attributed to ischemic time (time between the donor's death and sample collection

when blood flow is interrupted), we removed 10,737 DEGs associated to ischemic time in the GTEx aorta samples (N = 387)[16] from the total DEGs found between AAA and controls, leaving 3,002 DEGs (Additional file 1: Figure S2B and Additional file 5: Table S4).

154 We then performed a new enrichment analysis and identified 424 enriched GO terms and 65 155 KEGG pathways (Additional file 1: Figure S3B and Figure S4B) (Complete results are available 156 at Additional files 6 and 7: Tables S5 and S6, respectively), which represented removal of 728 157 and 24 pathways susceptible of being caused by ischemic time, respectively. Cluster analysis of 158 GO enriched terms confirmed identified clusters related to the regulation of calcium ion retention, ATP synthesis coupled electron transport, and immune response centered on T cell 159 160 activation (MHC class II protein complex, positive regulation of T cell activation). On the other 161 hand, other clusters also associated with the immune system were no longer represented 162 (regulation of mononuclear cell proliferation, leukocyte chemotaxis regulation of adaptive 163 immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains, CD4-positive, alpha-beta T cell differentiation, mast cell 164 165 degranulation) together with the regulation of actin filament length (Figure 2B). By accounting 166 for genes whose expression was altered by ischemic time, we identified a set of genes that are 167 less likely to be affected by the experimental limitations of these types of studies.

168 Vascular inflammation has been previously associated to AAA development and 169 progression[17,18]. Even in our most stringent analysis, which removed pathways possibly 170 caused by ischemic time, there was a notable enrichment of pathways associated with the 171 immune response. Consequently, we decided to investigate the influence of the inflammatory 172 infiltrate on AAA by comparing the abundance of 22 immune cell types from gene expression 173 profiles between our AAA and control samples. After correcting for multiple testing, we found 174 significant differences on the abundances of CD8 T-cells, natural killer (NK) resting cells, and 175 dendritic activated cells (Figure 2C). AAA samples had a higher proportion of CD8 T-cells, while

176 controls had more NK resting cells and dendritic activated cells. **Table 2** provides a summary of 177 the three cell populations with the highest and lowest presence in each group. The findings 178 support the previously reported involvement of CD8 T-cells and NK cells in AAA.[17,18] The 179 lower levels of dendritic cells detected in AAA were unexpected, as previous studies found 180 significantly higher levels of dendritic cells in AAA samples compared to controls[19].

181 Table 2: Summary of the three most and least prevalent cell populations in AAA and controls.

Cell Populations (AAA)	Percentage (%)	Cell Populations (Controls)	Percentage (%)
Plasma B cells	9.46	Resting mast cells	12.34
M2 macrophages	8.68	Resting memory CD4 T cells	8.31
Resting mast cells	6.99	M2 Macrophages	8.23
M1 macrophages	1.43	Eosinophils	2.03
Eosinophils	1.37	T cell follicular helper cells	1.94
Activated dendritic cells	1.13	M1 Macrophages	1.45

182

183 <u>Study of alternative splicing:</u>

184 The relevance of alternative splicing in the development of diseases, such as cancer, 185 neurological, and cardiovascular diseases has been well-established for years.[20] However, 186 capturing the complexity of alternative splicing has been challenging. With the recent 187 improvements in sequencing techniques it is now possible to study alternative splicing in more 188 depth.[20] We investigated alternative splicing patterns between the AAA and control groups 189 to identify specific splicing patterns associated with AAA. We identified 15 significant 190 alternative splicing events on eleven unique genes (FHL1, GNAS, ASAH1, SPP1, ARL1, MORF4L2, 191 CYCS, HMGB1, HMGN1, SELENOP, RNASE4) between AAA and controls. The analysis revealed 192 that, as anticipated, the number of altered alternative first exon events was more represented 193 than any other splice event among AAA and control samples (Figure 3A), consistent with

previous work suggesting that it is the most frequent splice event in the human genome[21] (Complete results are available in **Additional file 8: Table S7**). A functional enrichment analysis was conducted on the eleven genes with significant alternative splicing events, but no significantly enriched metabolic pathways were found. Interestingly, seven out of the eleven genes were also differentially expressed between AAA and controls, suggesting that the expression of specific splicing variants could be altered in AAA (**Figure 3B**).

200 <u>Differential expression analysis by aortic diameter</u>:

The diameter of AAA is a significant risk factor for rupture. We analyzed the DEGs by diameter to identify alterations in gene expression throughout the progression of the disease. We observed a total of 32 DEGs among aneurysms of varying diameters (N = 84), although no enriched pathways were identified (Additional file 1: Figure S2C and Additional file 9: Table S8). Of the 32 DEGs by diameter, eight were also DEGs between AAA and controls (Figure 3C), suggesting that these eight genes are relevant for disease formation and also during disease progression.

208 <u>Allelic specific expression:</u>

209 We investigated the potential effect of AAA-associated genetic variants on gene expression in 210 diseased tissue by studying allele specific expression in twelve AAA samples with available 211 genetic data. On average, we identified 529 genes with significant allele specific expression 212 (adjusted p-value < 0.05) in the twelve AAA samples. Among these genes, 90 exhibited 213 significant allele specific expression in more than five of the twelve AAA samples. Additionally, 214 to determine whether these associations were related to AAA or were characteristic of the 215 aortic tissue, we compared allele specific expression patterns between our AAA samples and 216 387 GTEx aortic samples, used as controls. The comparison between AAA and control samples 217 identified 1,815 genes with significant differences in the allele specific expression patterns 218 (adjusted p-value < 0.05) (Figure 4A). An enrichment analysis on GO terms for these 1,815

genes revealed 91 enriched pathways. The posterior cluster analysis revealed three clusters strongly related to the immune system: MHC protein complex, positive regulation of T cellmediated cytotoxicity, and regulation of T cell activation (Figure 4B). The association between the immune system and AAA was also observed in the differential expression analysis between AAA samples and controls, validating the robustness of these results.

224 Finally, among the 90 genes that exhibited significant allele specific expression in more than 225 five AAA samples, we selected those that also showed significant differential allelic specific 226 expression analysis between AAA and GTEx control samples, and those present in loci 227 identified in the largest genome-wide association study (GWAS) on AAA risk[7], in order to 228 identify haplotypes associated with AAA risk. Among the selected genes, SNURF was the only 229 gene that also presented differential allele specific expression patterns between AAA and 230 control tissues, and SPP1 and THBS2 were prioritized based on their presence in a locus 231 identified in the previous GWAS on AAA. This allowed to hypothesize that the presence of 232 particular genetic haplotypes in these three genes determined their differential expression 233 associated with risk of AAA.

234 DISCUSSION:

235 This study analyzes differential expression between AAA aortic tissue samples and control 236 aortic samples using whole transcriptome data obtained through RNAseq. In addition, we 237 studied the effect of ischemic time on gene expression, to obtain a more credible list of genes 238 associated with AAA development. Using our RNAseq data, which provides superior alternative 239 splicing analysis compared to microarrays[22], we conducted a novel exploration of alternative 240 splicing between AAA and control samples, to identify potential causes of the observed 241 differential expression. Furthermore, we analyzed the differential expression between AAA of 242 different diameters to study the genes altered during disease progression. Finally, we analyzed

allele specific expression to gain insights into how genetic variants impact expression in the

diseased tissue.

245 <u>Study of ischemic time-independent pathways involved in AAA development:</u>

246 Clustering analysis with the enriched pathways after accounting for the ischemic time effect 247 revealed a strong association with MHC class II protein complex, positive regulation of T-cells, 248 and intracellular calcium ion regulation. Additionally, we have for the first time identified the 249 regulation of the ATP synthesis pathway in a differential expression analysis of aortic samples. 250 While the detection of the ATP synthesis regulatory pathway is novel, it is in line with previous 251 work associating mitochondrial disfunction and AAA [23,24]. On the other hand, previous 252 differential expression studies in microarrays between AAA and control aortic tissue have 253 consistently found associations of immune system pathways with AAA.[10-13,15] Our results 254 confirm these associations and demonstrate that these are independent of the ischemic time, 255 which is a confounder factor in most studies using donor samples. Finally, the regulation of 256 intracellular calcium was previously detected in one study of differential expression between 257 dilated and non-dilated aortic samples[11]. Our analyses confirm that this association is 258 independent of ischemic time.

259 We identified for the first time several enriched signaling pathways, with a large presence of 260 genes that code for subunits of complexes I (NADH ubiquinone oxidoreductase)), III (Ubiquinol-261 cytochrome c reductase) and IV (cytochrome c oxidase)) of the electron transport chain. Our 262 results indicate that 88 % (22 / 25) of the DEGs coding for the subunits of the complexes that 263 form the electron transport chain are expressed to a lower extent in AAA, suggesting a lower 264 synthesis of ATP in AAA tissue. Mitochondrial dysfunction has previously been studied in the 265 development of AAA[23,24] and other cardiovascular diseases[25] due to its key role in some 266 of the cellular alterations characteristic of cardiovascular diseases, including excessive 267 production of reactive oxygen species, energy depletion, endoplasmic reticulum stress, and

activation of apoptosis. However, this is the first time that these metabolic pathways have been
characterized in a DEGs study of AAA, confirming the role of mitochondrial dysfunction on AAA.

270 Among the genes present in all the enriched signaling pathways related to intracellular calcium 271 regulation, APLNR[26], F2R[27], GPER1[19], JPH2[28], PKD2[29] and THY1/CD90[30] have 272 already been investigated for their role in AAA. However, six additional genes are present in all 273 pathways: ABL1, CALM1, CALM2, RYR2, SRI and CD19. Except for CALM2, all of them have been 274 previously identified as DEGs in previous microarray studies between AAA and control 275 samples[10-12,15], but none of these genes have been further investigated in either functional 276 or epidemiological studies. These genes are closely related to intracellular calcium metabolism. 277 ABL1 participates in both the release of stored intracellular calcium and extracellular calcium 278 entry[31]. CALM1 and CALM2 code for two isoforms of the calmodulin protein, which plays a 279 crucial role in the contraction of vascular and cardiac tissue through the detection of 280 intracellular calcium[32]. RYR2 is mainly expressed in cardiac tissue and codes for the main 281 regulator of sarcoplasmic calcium release[33]. SRI codes for the main binding protein of the 282 RYR2 gene product[34]. The comparison between our AAA and control samples shows a 283 downregulation of all these genes, suggesting a decrease in intracellular calcium levels in 284 smooth muscle cells, consistent with loss of vascular contractility in the dilated aorta[35].

On the other hand, we observed upregulation of the *CD19* gene in AAA. The activation of the surface protein encoded by *CD19* triggers the release of intracellular calcium, which contrasts with the previous results[36]. However, *CD19* is also a biomarker of B-cell development [36] which also play a key role in the development of AAA[37].

Among the pathways that were previously identified in differential expression analyses between AAA and control tissue is inflammation. There is a widely studied inflammatory component in AAA development involving both, adaptative and innate immune responses [17,18]. The presence of inflammatory infiltrates in AAA tissue have been widely

demonstrated, which play a key role in the development of the disease[17,18]. The results of
our cluster analysis also corroborated the association with the immune system after accounting
for ischemic time, highlighting the key role of T cells on AAA development[38,39].

296 To better understand the effects of the inflammatory infiltrate in AAA development, we 297 compared the proportions of inflammatory infiltrates between AAA and control samples. Some 298 previous studies have analyzed the inflammatory infiltrates in AAA tissue[15,19,40]. In one 299 study[15], immune cell proportions were estimated in AAA tissue layers (media and adventitia), 300 without comparing with controls. Our results strongly corroborate their findings, suggesting 301 that plasma B cells and M2 macrophages were the two most represented cell populations in 302 both layers, and M1 macrophages, eosinophils, and activated dendritic cells were among the 303 least represented cells in both layers. Surprisingly, resting mast cells emerged as our third most 304 represented cell group, while in the layer-specific analysis, mast cells represented a small 305 percentage of the total inflammatory cells. This contrasts with another study that compared 306 whole-tissue samples between AAA and controls[19], where resting mast cells were among the 307 most frequent cell groups in AAA samples. In addition, our results align with this study in 308 detecting higher proportions of CD8 T-cells and lower proportions of resting NK cells in AAA 309 samples. However, a discrepancy was noted in the levels of activated dendritic cells, which 310 were more present in controls in our study but slightly higher in AAA samples in the previous 311 work. Additional single-cell data demonstrated a higher proportion of T follicular helper cells 312 and lower proportions of M1 and M2 macrophages in AAA samples compared to controls[40].

To rule out the effect of death as potential cause of variability, we used a reference work that evaluated the effect of death in blood samples,[41] which found higher levels of resting NK cells and CD8 T-cells in post-mortem samples. These results suggest that the increase in CD8 Tcells levels in AAA tissue could be even greater than the one we observed, and that the greater presence of NK resting cells in control samples could be due, in part, to their origin from organ

donors. Consistent with this hypothesis, previous studies have shown that levels of NK cells are
higher in the peripheral blood of AAA patients compared to controls, [42] and that these cells
play a role in the development of the disease[18]. These results also suggest the existence of a
highly cytotoxic environment led by CD8 T-cells in AAA tissue.
The lower levels of activated dendritic cells in the AAA samples compared to the controls was

unexpected, given their established role as AAA inducers[17,19]. These results suggest that, although dendritic cells may participate in the development of AAA, they are not part of the inflammatory infiltrate.

326 <u>Study of alternative splicing between AAA and controls</u>:

327 This is the first study to elucidate the role of splicing in AAA development. We compared splice 328 events between AAA and controls and identified eleven genes (SPP1, FHL1, GNAS, MORF4L2, 329 HMGN1, ARL1, RNASE4, ASAH1, CYCS, HMGB1, SELENOP) with differentially represented 330 splicing variants. We compared the splice events types identified in our comparison between 331 AAA and controls samples with the presence of splicing events in the whole genome [21] and 332 the observed proportions were comparable to the expected values genome-wide. The most 333 frequent splicing types were alternative first exon (60 %) and skipping exon (20 %), while the 334 least frequent were alternative 5' splice-site (13.3 %) and mutually exclusive exon (6.67 %). On 335 the other hand, it was surprising that our results did not include alternative last exon, 336 alternative 3' splice-site, and retained intron, despite their considerable genome-wide 337 frequencies (10.72 %, 9.2 % and 3.54 %, respectively). This may be due to the limited sample 338 size, as only 15 events were identified.

We observed seven genes that showed differential expression between AAA and control samples and had a splicing variant significantly more represented in AAA or controls (*SPP1*, *FHL1*, *GNAS*, *MORF4L2*, *HMGN1*, *ARL1*, *RNASE4*), indicating that splicing differences could be explaining the observed differential expression. Among these genes, *SPP1* and *FHL1* have been

343 previously characterized in relation to AAA[43,44], whereas GNAS is a new DEG identified 344 between AAA and control tissue. The evidence of differential splicing events validates GNAS as 345 a new robust DEG between AAA and control tissue, and suggests that alternative splicing in this 346 gene explains the differential expression and its implication to AAA. Finally, MORF4L2, HMGN1, 347 ARL1 and RNASE4 although they have been identified in previous differential expression 348 studies in relation to AAA[10–15], their specific role in AAA has not been studied. For these 349 genes, our results contribute to understand the molecular mechanism leading to differential 350 expression in AAA tissue.

351 SPP1 codes for the osteopontin protein, an important regulator of inflammation that has 352 described functions in cardiovascular diseases[45]. SPP1 is more expressed in AAA tissue than 353 controls, both in animal models and in humans, and it participates in AAA-associated 354 extracellular matrix degradation[46,47] through the nuclear factor kappa B signaling pathway. 355 It is also known that the SPP1 gene undergoes splicing and gives rise to 3 distinct isoforms osteopontin a, osteopontin b and osteopontin c, with specific characteristics, which have not 356 357 been characterized in AAA. Consistent with previous data, our results found increased 358 expression in AAA tissue, and identified for the first time that that skipping of exon 3 on SPP1 359 gene is more frequent in AAA than in controls, suggesting that this form of alternative splicing 360 may be important for the development of AAA.

FHL1 codes for a protein that is highly expressed in skeletal and cardiac muscle. *FHL1* has been shown to be a promising blood biomarker for human ascending thoracic aortic aneurysm as a modulator of metalloproteases.[44] Our findings, and those obtained in previous microarray studies[10–13,15], indicate that *FHL1* levels are lower in AAA than in controls. We have detected for the first time that an alternative 5' splicing-site form in this gene occurs more frequently in the control group, suggesting that AAA tissue would have reduced expression of this alternative isoform and reduced levels of *FHL1*, leading to higher risk of AAA development.

368 Although not previously found in transcriptomic studies, mutations in the GNAS gene have 369 been studied in mice for their effect promoting AAA[48]. GNAS codes for the alpha subunit of 370 the heterotrimeric G stimulatory protein (Gs α). Gs α may play a protective role in AAA 371 development through regulation of vascular muscle tissue and is considered a potential 372 therapeutic target[48]. Consistent with this protective role, our results confirmed lower 373 expression GNAS levels in AAA. Moreover, our results add a mechanistic insight by revealing an 374 alternative first exon splicing variant that occurs more frequently in controls and that could 375 increase expression levels of the final protein and protect against AAA.

376 *MORF4L2* and *HMGN1* are DNA repair related genes, which had significantly lower and higher 377 expression levels in AAA tissue compared to control tissue, respectively. *MORF4L2* has been 378 associated with atheroma plaque progression in atherosclerosis[49]. Both genes present 379 alternative splicing events that are less frequent in AAA tissue. Further work to elucidate the 380 specific role of these genes in the risk of AAA development is warranted.

381 Genes associated with AAA onset and progression:

382 We identified eight genes (EXTL3, ZFR, DUSP8, DISP1, USP33, VPS37C, ZNF784, RFX1) that 383 showed differential expression between AAA and control tissues, and also differential 384 expression in AAA tissues of different diameters. Among these, EXTL3, ZFR, DUSP8, and DISP1 385 have been previously identified as DEGs between AAA and controls but their role in AAA 386 progression is novel.[10–15], and USP33, VPS37C, ZNF784 and RFX1 are novel DEGs. This could 387 indicate that the genes may have a role beyond the disease onset and could be potential 388 therapeutic targets to halt aneurysm expansion. Therefore, the potential contribution of these 389 genes to the development of AAA needs to be thoroughly investigated.

Among the genes with higher expression at larger diameters, *USP33* encodes a deubiquitinating enzyme that has been associated with the development of hypertension[50], a known risk factor for AAA[51]. Proteins with deubiquitinating functions have been proposed

as possible candidate genes for the treatment of AAA and other cardiovascular diseases[52]. Additionally, *USP33* promotes the stabilization of beta2-adrenergic receptors, which promote vasodilation in smooth muscle[53]. We observed an increase in *USP33* expression with increased AAA diameter, which is consistent with the functionality of beta2-adrenergic receptors. These results suggest that the *USP33* gene may be a potential candidate for the treatment of AAA.

399 Among the genes that exhibit lower expression levels with larger diameters, we highlight 400 DUSP8 and RFX1. DUSP8 is a phosphatase that negatively regulates the MAP kinase pathway, 401 which is linked to cell differentiation and proliferation[54]. Previous studies have shown that 402 DUSP8 expression levels are downregulated in mouse models of aortic dilatation[55], and the 403 dual specificity phosphatase 8 protein (DUSP8) acts as a regulator of cardiac dynamics[54]. Our 404 findings align with those obtained in the animal model of aortic dilatation, suggesting that 405 DUSP8 may be a potential candidate gene for treating AAA by regulating both aortic dilatation 406 and the immune system. RFX1 encodes a transcription factor that regulates genes involved in 407 MHC class II[56]. In a previous bioinformatics study using microarray data, RFX1 was identified 408 as a transcription factor that could potentially regulate DEGs between AAA and controls 409 through its downregulation[57]. Previous research has shown that a decrease in *RFX1* expression leads to activation of CD14⁺ monocytes in CAD patients[58]. Furthermore, CD14 410 411 protein plays a crucial role in recruiting macrophages during the early stages of AAA, and 412 knockout mice for CD14 gene have been shown to resist the formation of AAA in two different 413 models[59]. Finally, our expression results indicate that CD14 is upregulated in AAA patients 414 compared to controls (FDR P-value = 0.002). In conclusion, these results suggest that low 415 expression levels of the transcription factor RFX1 may lead increased CD14 expression, which 416 plays a crucial role in the development and progression of AAA by recruiting macrophages.

417 Two previous studies have considered the diameter of AAA in differential expression analyses 418 with aortic tissues. The first study[10] compared gene expression between small (n = 20) and 419 large AAA (n = 29) with controls, but did not compare AAA of varying diameters. The second 420 study[15] performed a correlation analysis on each gene between the diameter growth rate 421 and gene expression in individuals (n = 24) with two aortic measurements, distinguishing 422 between the media and adventitia aortic layers but did not identify any significant genes after 423 multiple testing correction. The larger sample size in our study have enabled to identify for the 424 first time genes that are associated to aneurysm progression, which could be potential 425 therapeutic targets.

426 Identification of haplotypes associated with AAA risk:

427 We performed a clustering analysis of enriched biological pathways with the 1,815 genes with 428 significant differences in the allele specific expression patterns between AAA and controls. The 429 cluster analysis revealed a strong association with immune system pathways, particularly those 430 associated with T cells. These results are consistent with the clustering analysis of DEGs 431 between AAA and controls and demonstrate how specific haplotypes determine the 432 differential expression of genes associated with AAA in the diseased tissue. By combining allele 433 specific expression information on AAA samples with the allelic specific expression results 434 between AAA and controls, along with information from a previously published GWAS[7], we 435 explored the associations between genetic variants associated with AAA risk and gene 436 expression. This approach aimed to unravel the association between genetic haplotypes and 437 gene expression as determinants of AAA risk.

438 *SNURF* is the only gene that showed significant allelic specific expression in more than five of 439 the twelve studied individuals with AAA and differential allelic specific expression patterns 440 between AAA and controls suggesting the existence of a specific haplotype associated with less 441 expression in AAA and leading to higher risk of AAA. *SNURF* codes for an open reading frame of

442 the SNRPN gene, with which it forms a bicistronic gene[60]. Both genes exhibit significantly 443 lower expression in AAA than in controls in our data. Moreover, we observed that rs705 single 444 nucleotide polymorphism (SNP) (minor allele frequency (MAF) (C) = 0.45) determined SNURF 445 expression in eight out of twelve AAA samples, where the T allele was associated with double 446 expression amounts compared to the C allele. Additionally, rs705 is an eQTL in blood of the 447 SNRPN gene. Although causality cannot be derived from these results, these results suggest a 448 possible effect of the haplotype containing the rs705 T allele on this locus on SNURF 449 expression, resulting in higher risk for AAA development.

450 Among the genes with significant allele specific expression in the twelve analyzed AAA samples 451 that did not exhibit significant allele specific expression patterns between AAA and control 452 groups in our analyses, we selected those that were part of a locus associated to AAA in the 453 most recent GWAS on AAA risk[7]. THBS2 encodes for thrombospondin 2, a protein that 454 regulates cell-cell and cell-extracellular matrix interactions and has been studied in relation to multiple cardiovascular diseases[61]. THBS1, a member of the same family, has been identified 455 456 as a regulator of AAA in animal models[62]. Our allele specific expression results suggest that 457 the expression of this gene could be associated with AAA development, supporting the 458 implication of the gene in AAA risk. Two common genetic variants (rs58023137 (MAF (T) = 0.22) 459 and rs9505895 (MAF (A) = 0.2)) were identified in previous GWAS studies[7] and in our allele 460 specific expression results. For both variants, the GWAS risk allele was associated with higher 461 expression gene levels in one individual with AAA. Additionally, these two variants were also 462 eQTLs in aortic tissue regulating THBS2 gene expression, confirming the known association 463 between thrombospondin and AAA[7], and demonstrating the presence of risk haplotypes 464 associated to increased expression and risk of AAA.

465 Regarding the SPP1 gene, we found six genetic variants (rs35893069 (MAF (T) = 0.1), rs6839524
466 (MAF (G) = 0.12), rs4754 (MAF (C) = 0.28), rs1126616 (MAF (T) = 0.27), rs1126772 (MAF (G) =

467 0.21), rs9138 (MAF (C) = 0.22)) with allele specific expression among the twelve AAA samples.
468 As previously discussed, the *SPP1* has been associated to AAA risk due to the role of the
469 protein osteopontin, which it encodes, in the degradation of the extracellular matrix that is
470 characteristic of AAA[46,47]. However, none of the six genetic variants were found to be
471 significant in the previous GWAS[7], and therefore no association with allelic expression could
472 be established.

473 <u>Strengths and limitations and comparison with previous studies</u>

474 This is one of the largest studies of differential expression between AAA tissue samples and 475 controls. However, due to the difficulty in obtaining aortic tissue samples, the sample size is 476 still limited compared to transcriptomic studies in more accessible tissues, which may have 477 limited our power. Previous studies comparing transcriptomics between AAA and control 478 samples have been limited to the use of expression microarrays [10–15]. In this study, we used 479 RNAseq to obtain transcriptomic information. RNAseq provides greater sensitivity, a wider 480 range of detection of both high and low expression genes, and is not limited to microarray 481 probes[9,63], which allowed us to detect more DEGs. Additionally, RNAseq technology allowed 482 for a more precise study of alternative splicing compared to microarrays.

Accounting for ischemic time enabled us to more accurately identify biological processes associated to AAA, thereby minimizing differences in sample origins between AAA and controls. At the same time, despite ensuring more robust findings, the elimination of these genes could have been too rigorous and imply the loss of some biological pathways associated with AAA that, at the same time were affected by ischemic time.

The significant phenotypic differences in age and sex between individuals recruited as AAA and controls are a limitation of the study. Moreover, the analyses of the allele specific expression are limited by the small sample size (n = 12) and the requirement for the individuals to be heterozygous in order to study the genetic variants. Therefore, further validation is necessary.

However, this is the first study analyzing allele specific expression in AAA and our results
emphasize the value of this new dataset combining genetic and expression data for the study
of AAA.

495 Finally, the conclusions presented in this article are based on the results obtained from a
496 cohort of European- ancestry individuals only. Further analyses in different ancestries will
497 determine the generalization of these results.

498 **CONCLUSIONS**

499 Our analysis of the whole transcriptome has enabled us to identify numerous novel genes that 500 were not previously detected in microarray studies. Additionally, our efforts to account for the 501 impact of ischemic time have provided more robust implicated biological pathways that lead to 502 AAA development. Among these pathways, ATP synthesis regulation (i.e. genes encoding 503 subunits I, III and IV of the electron transport chain), has been associated for the first time in 504 transcriptomic studies of AAA tissue, although this pathway was previously studied in relation 505 to AAA in previous studies[23,24]. Additionally, the study of differential splicing processes 506 between AAA and controls have revealed novel molecular processes involving already known 507 genes in relation to AAA, such as SPP1, FHL1 or GNAS.

The study also analyzed the differential expression of genes in individuals with AAA of different diameters, providing valuable insights into the underlying molecular mechanisms contributing to AAA progression. Further research on these genes may lead to potential treatments against aneurysm expansion, which increases the risk of rupture. Finally, the analysis of differential allele specific expression in twelve AAA has allowed the identification of haplotypes associated with expression of certain genes and AAA risk, providing evidence for their involvement in disease, and shedding light into the molecular mechanism.

515 Overall, this study provides a comprehensive exploration of AAA expression patterns, revealing 516 key insights into the pathophysiology of AAA initiation and progression. RNAseq was used to

517 conduct one of the largest differential expression analyses to date, uncovering numerous genes 518 associated with AAA. Our consideration of ischemic time and AAA diameter improved the 519 precision in identifying biological processes associated with AAA onset and progression. 520 Furthermore, our analysis of differential allele specific expression has identified genetic 521 haplotypes that influence gene expression on AAA tissue, which advances our understanding of 522 AAA genetic background. These findings contribute to future research and potential advances 523 in precision medicine to reduce AAA progression and mortality risk.

524 METHODS:

525 <u>Subjects:</u>

526 We used a total of 140 human abdominal aortic samples from 96 patients diagnosed with 527 infrarenal AAA and undergoing open surgery for AAA repair at Hospital de la Santa Creu i Sant 528 Pau and Hospital del Mar (Barcelona) and 44 controls. The study participants were obtained 529 from TABS cohort, which includes genomic, transcriptomic, clinical, and maximum aneurysm 530 size data, from AAA patients and healthy individuals. Maximum aortic diameters were obtained 531 from computed tomography or ultrasound images. Genomic data were obtained through 532 genotyping using the Infinium Global Screening Array-24 v2.0 from Illumina (San Diego, 533 California) (coverage 665,608 variants) and imputation to the TOPMED Reference Panel. Only 534 variants with imputation quality > 0.3 were used for the allele specific expression analyses. 535 Healthy abdominal aortas were obtained from 21 male and 23 female multiorgan donors 536 (Table 1).

537 <u>Sample processing</u>:

A portion of tissue sample was placed in RNAlater solution (Qiagen GmbH, Hilden, Germany) and stored for 24 hours at 4 °C before long-term storage at –80 °C until further processing. For RNA isolation, tissues were then homogenized in 1 ml Trizol (ambion, Carlsbad, CA) in the FastPrep-24 homogenizer and Lysing Matrix D tubes (MP Biomedicals, Solon, OH) and RNA was

542 purified using PureLink RNA Mini Kit (Invitrogen, Carlsbarg) following the manufacturer's 543 recommendations. RNA concentration was measured using Nanodrop 200 (Thermo Scientific). 544 RNA integrity was assessed on Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). RNA 545 integrity number (RIN) was recorded and only samples with a RIN higher than 6 were used. 546 RNA sequencing: 547 We performed sequencing analyses using Illumina NovaSeq 6000, with a read length of 150 bp 548 and paired-end sequencing. Two sequencing runs were performed to reduce the variability of 549 the technical variables. First, AAA and control samples were randomized between sequencing 550 plates. Second, only AAA were sequenced with as little technical variability as possible. In all 551 sequencing runs, a minimum of 30 million reads were required, repeating the sequencing on a

new plate if this limit was not reached.

553 <u>Alignment, quantification, and quality control:</u>

554 We used STAR v.2.5.3a[64] to perform the alignment on the reference genome version GRCh38 555 and we then used RSEM v1.3.0[65] for gene quantification. For both analyses, we used gene 556 models from GENCODE v26 gene annotation file[66]. In total, 58,219 genes were quantified. Of 557 these, we selected protein coding genes and long non-coding RNA (IncRNA) genes that had 558 been either experimentally validated (level 1 annotation) or manually annotated (level 2 559 annotation)[66], resulting in 27,290 genes (19,777 protein-coding and 7,513 lncRNA) for 560 further analyses. Gene quantifications were expressed as Transcripts Per Million (TPMs), which 561 were obtained by normalizing for gene length first, and then for sequencing depth. This 562 ensured that the sum of all TPMs in each sample was the same, facilitating the comparison 563 between samples. All samples reached a minimum of 10 million reads aligned to the reference 564 genome with STAR (Additional file 1: Figure S5A-5B)[64].

As part of the quality control, we also checked that the reported sex of the samples matched the biological sex of the sequenced data. To do this, we compared the expression levels of the *XIST* gene, which regulates the X chromosome inactivation mechanism in females and has null expression in males, with the expression of male exclusive genes, calculating an average expression of Y chromosome genes. One sex mismatch sample was eliminated from the study (Additional file 1: Figure S5C).

571 <u>Differential expression analysis:</u>

572 Before conducting differential expression analyses, we normalized the TPMs counts using 573 quantile normalization and removed lowly expressed genes by removing genes with less than 574 0.5 TPMs in more than 50% of the samples. For the comparison of AAA against control 575 samples, we kept 14,675 genes and removed 12,615 genes. For the comparisons among AAA 576 using the AAA-only sequencing panel, we kept 14,779 genes and removed 12,511 genes.

To evaluate the impact of technical covariates on the results, we performed a Principal Components (PC) Analysis on all samples and tested the correlation between the PC Analysis and all the technical covariates. Technical covariates that had significant correlations (p-value < 0.05) with the first four PC were included in the analyses as fixed effect covariates. Additionally, all comparisons were adjusted for age and sex. To preserve the regulatory effects that act through smoking, we did not include smoking as a covariate (Additional file 10: Table S9).

First, we calculated DEGs between AAA and controls using a linear regression, including age, sex, flow cell type, flow cell lane, GC mean content (GC mean), RIN, percentage of RNA fragments > 200 (DV200), and Qubit as covariates. Date of creation of the library was not included due to its high correlation with the case/control variable (Pearson's correlation = -0.74) (Additional file 1: Figure S6A-6B)). Second, we calculated DEGs between aneurysms of varying diameter using a linear regression, including age, sex, date of creation of the library, batch number, GC mean, RIN, DV200 and Qubit. We corrected for multiple testing in both

analyses using Benjamini-Hochberg false discovery rate (FDR) method and considered
significant DEGs those with an adjusted p-value below 0.05[67].

We then performed a linear regression model to identify genes whose expression could be altered by ischemic time, using ischemic time information on artery aorta tissue samples from GTEx V8 data[16]. We corrected the linear regression model for age, sex, RIN, type 2 diabetes, body mass index, autolysis score, center, sequencing protocol, sequencing platform, and genotyping PC. To determine the genes affected by ischemic time, we corrected for multiple testing and selected genes with an FDR-adjusted p-value lower than 0.05[67]. All analyses were performed in R.

599 Enrichment analysis:

600 After identifying DEGs between AAA and control samples and between AAA of varying 601 diameters, we performed enrichment analyses using the R package 'clusterprofiler' [68,69] on 602 the Gene Ontology (GO) databases for Biological Process, Cellular Component and Molecular 603 Function, as well as the Kyoto Encyclopedia of Genes and Genomes (KEGG)[70]. We corrected 604 for multiple testing using the Benjamini-Hochberg FDR method and identified significantly 605 enriched pathways with an adjusted p-value below 0.05[71]. We used 'aPEAR'[72] to perform a 606 cluster analysis of redundant pathways with a minimum cluster of size of 15 and hierarchical clustering. The enriched pathways and genes were visualized using 'enrichplot' [73]. 607

608 <u>Study of the inflammatory infiltrate</u>:

We investigated the differences in the proportions of inflammatory infiltrates between AAA and control samples using CIBERSORTx[74]. CIBERSORTx compares RNAseq data with a reference expression database of selected cell types, to estimate the proportion of each cell type. The residuals of our RNA-seq data were calculated using a linear regression that included all covariates except the status variable. We used the residuals and the 'Im22' signature matrix, that contains expression data of 547 genes in 22 inflammatory cell types from microarray

studies, and can be used to distinguish inflammatory cell populations in RNA-seq data[74]. We conducted a t-test to compare the proportions of each cell type between AAA and controls. A p-value threshold corrected by multiple testing using Bonferroni for the number of cell types was set at p-value < 2.27×10^{-3} (0.05 / 22).

619 <u>Alternative splicing:</u>

620 We used the SUPPA2 software to identify differences in splice events between AAA and control 621 tissue samples. SUPPA2 can identify seven different splice events including skipping exons, 622 mutually exclusive exons, alternative 5' or 3' splice sites, retained introns, and alternative first 623 or last exons. Based on gene annotation from GENCODE v26,[66] we computed the proportion 624 of splice inclusion for the TPMs counts in each splice event by dividing the number of TPMs of 625 one form of the event by the total number of TPMs. Finally, the magnitude of splicing change 626 was calculated by subtracting the proportion of splice inclusions between AAA and controls. 627 Significant alternative splicing events were selected based on a magnitude of splicing change 628 higher than 0.1 and FDR-corrected p-values lower than 0.05, using the default parameters for 629 calculation.

630 <u>Allelic specific expression</u>:

Allele specific expression was investigated using PHASER[75] on twelve AAA samples with genotype data. Allele specific expression consists of the analysis of the differences in the expression levels of the different haplotypes present in a heterozygous individual. We quantified allele specific expression at the gene level using the GENCODE V26 gene annotation[66]. To reduce the effect of the known mapping bias towards the reference allele[76], we performed an additional STAR mapping step with WASP filtering[77].

637 We used the allele specific expression data obtained by the GTEx consortium to compare allele 638 specific expression between our AAA samples and GTEx control tissues[78]. To do this, we 639 compared the proportional expression of each allele between our AAA samples and the GTEx

- 640 controls, using a non-parametric Wilcoxon test[79]. Then, to identify genes with distinct allele
- 641 specific expression patterns, we corrected for multiple comparisons using FDR[67]. We
- 642 performed enrichment and cluster analyses in all genes showing FDR adjusted p-values lower
- 643 than 0.05.
- **ABBREVIATIONS**
- **AAA** abdominal aortic aneurysm
- **DEGs** differentially expressed genes
- **TABS** triple A Barcelona study
- 648 LncRNA long non-coding RNA
- **TPMs** transcripts per million
- **PC** principal component
- 651 GC mean GC mean content
- **DV200** percentage of RNA fragments > 200
- **FDR** false discovery rate
- **GO** gene ontology
- **KEGG** Kyoto encyclopedia of genes
- **MHC** major histocompatibility complex
- **GWAS** genome-wide association study
- **ATP** adenosine triphosphate
- **Gsα** heterotrimeric G stimulatory protein
- **DUSP8** dual specificity phosphatase 8 protein

- 661 **SNP** single nucleotide polymorphism
- 662 **MAF** minor allele frequency
- 663 **DECLARATIONS**
- 664 <u>Ethics approval and consent to participate</u>:
- 665 The study was approved by the Hospital de la Santa Creu i Sant Pau Ethics Committee (IIBSP-
- 666 OMI-2019-102). All patients gave written informed consent prior to surgery to participate in
- the study. The study conformed to the principles of the Declaration of Helsinki.
- 668 <u>Consent for publication</u>:
- 669 Not applicable.
- 670 <u>Availability of data and materials</u>:
- The personal data used for this study is available from the corresponding author on reasonable
- 672 request for collaborations provided it complies with the ethical permits of the study. All other
- 673 data supporting the findings of this study is available within the paper and its Supplementary
- 674 Information. Code used for data preparation and analysis is available at
- 675 https://github.com/Gerardts9/RNAseq.
- 676 <u>Competing interests</u>:
- 677 The authors declare that they have no competing interests.
- 678 Funding:

This work was supported by a grant from the Spanish Ministry of Science and Innovation (PID2019-109844RB-I00). The genotyping service was carried out at the Genotyping Unit-CEGEN in the Spanish National Cancer Research Centre (CNIO), supported by Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación. CEGEN is part of the initiative IMPaCT-GENÓMICA (IMP/00009) cofunded by ISCIII and the European Regional Development
Fund (ERDF). GT-S is supported by the Pla Estratègic de Recerca i Innovació en Salut (PERIS)
grant from the Catalan Department of Health for junior research personnel
(SLT017/20/000100). MS-L is supported by a Miguel Servet contract from the ISCIII Spanish
Health Institute (CPII22/00007) and co-financed by the European Social Fund. DD was funded
by a Tenovus Scotland Research PhD studentship, T19-06.

689 <u>Author's contributions</u>:

- 690 AV, MC, and MS-L conceived and designed the study. BS, JD, OP, LC, LN and J-RE generated the
- 691 clinical database and supplied the samples. GT-S and DD performed the analyses. GT-S, AB, AV,
- 692 MC, and MS-L interpreted the results. GT-S, AV, MC, and MS-L wrote the manuscript. All
- authors read and approved the final manuscript.

694 <u>Acknowledgments</u>:

- 695 We acknowledge the AAA patients at Hospital de la Santa Creu i Sant Pau and Hospital del Mar
- 696 who participated in this study, and the multiorgan donor families who made this research
- 697 possible through their generous consent.

698 <u>Author's information</u>:

699 AV, MC, and MS-L contributed equally to this work as senior authors.

700 **REFERENCES**

- Aggarwal S, Qamar A, Sharma V, Sharma A. Abdominal aortic aneurysm: A
 comprehensive review. Exp Clin Cardiol 2011;16:11-5.
- Kuivaniemi H, Ryer EJ, Elmore JR, Tromp G. Understanding the pathogenesis of abdominal aortic aneurysms. Expert Review of Cardiovascular Therapy 2015;13:975–87.
- Holmes DR, Liao S, Parks WC, Thompson RW. Medial neovascularization in abdominal
 aortic aneurysms: a histopathologic marker of aneurysmal degeneration with
 pathophysiologic implications. J Vasc Surg 1995;21:761–71; discussion 771-772.

708 709 710 711	4.	Robinson WP, Schanzer A, Li Y, Goodney PP, Nolan BW, Eslami MH, et al. Derivation and validation of a practical risk score for prediction of mortality after open repair of ruptured abdominal aortic aneurysms in a U.S. regional cohort and comparison to existing scoring systems. J Vasc Surg 2013;57:354–61.
712 713 714	5.	Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. Journal of Vascular Surgery 2018;67:2-77.e2.
715 716 717	6.	Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, et al. The Aneurysm Detection and Management Study Screening Program: Validation Cohort and Final Results. Archives of Internal Medicine 2000;160:1425–30.
718 719 720	7.	Roychowdhury T, Klarin D, Levin MG, Spin JM, Rhee YH, Deng A, et al. Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. Nat Genet 2023;55:1831–42.
721 722	8.	Lowe R, Shirley N, Bleackley M, Dolan S, Shafee T. Transcriptomics technologies. PLoS Comput Biol 2017;13:e1005457.
723 724	9.	Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009;10:57–63.
725 726 727	10.	Biros E, Gäbel G, Moran CS, Schreurs C, Lindeman JHN, Walker PJ, et al. Differential gene expression in human abdominal aortic aneurysm and aortic occlusive disease. Oncotarget 2015;6:12984–96.
728 729 730	11.	Lenk GM, Tromp G, Weinsheimer S, Gatalica Z, Berguer R, Kuivaniemi H. Whole genome expression profiling reveals a significant role for immune function in human abdominal aortic aneurysms. BMC Genomics 2007;8:237.
731 732 733	12.	Biros E, Moran CS, Rush CM, Gäbel G, Schreurs C, Lindeman JHN, et al. Differential gene expression in the proximal neck of human abdominal aortic aneurysm. Atherosclerosis 2014;233:211–8.
734 735 736 737	13.	Choke E, Cockerill GW, Laing K, Dawson J, Wilson WRW, Loftus IM, et al. Whole Genome- expression Profiling Reveals a Role for Immune and Inflammatory Response in Abdominal Aortic Aneurysm Rupture. European Journal of Vascular and Endovascular Surgery 2009;37:305–10.
738 739 740	14.	Gäbel G, Northoff BH, Weinzierl I, Ludwig S, Hinterseher I, Wilfert W, et al. Molecular Fingerprint for Terminal Abdominal Aortic Aneurysm Disease. J Am Heart Assoc 2017;6:e006798.
741 742 743 744	15.	Lindquist Liljeqvist M, Hultgren R, Bergman O, Villard C, Kronqvist M, Eriksson P, et al. Tunica-Specific Transcriptome of Abdominal Aortic Aneurysm and the Effect of Intraluminal Thrombus, Smoking, and Diameter Growth Rate. Arteriosclerosis, Thrombosis, and Vascular Biology 2020;40:2700–13.
745 746	16.	The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 2020;369:1318–30.

747 748	17.	Márquez-Sánchez AC, Koltsova EK. Immune and inflammatory mechanisms of abdominal aortic aneurysm. Front Immunol 2022;13:989933.
749 750 751	18.	Yuan Z, Lu Y, Wei J, Wu J, Yang J, Cai Z. Abdominal Aortic Aneurysm: Roles of Inflammatory Cells. Frontiers in Immunology [Internet] 2021 [cited 2022 Jan 25];11. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2020.609161
752 753	19.	Nie H, Qiu J, Wen S, Zhou W. Combining Bioinformatics Techniques to Study the Key Immune-Related Genes in Abdominal Aortic Aneurysm. Front Genet 2020;11:579215.
754 755 756	20.	Hasimbegovic E, Schweiger V, Kastner N, Spannbauer A, Traxler D, Lukovic D, et al. Alternative Splicing in Cardiovascular Disease—A Survey of Recent Findings. Genes (Basel) 2021;12:1457.
757 758	21.	Rotival M, Quach H, Quintana-Murci L. Defining the genetic and evolutionary architecture of alternative splicing in response to infection. Nat Commun 2019;10:1671.
759 760 761	22.	Romero JP, Ortiz-Estévez M, Muniategui A, Carrancio S, de Miguel FJ, Carazo F, et al. Comparison of RNA-seq and microarray platforms for splice event detection using a cross- platform algorithm. BMC Genomics 2018;19:703.
762 763	23.	Ouyang M, Wang M, Yu B. Aberrant Mitochondrial Dynamics: An Emerging Pathogenic Driver of Abdominal Aortic Aneurysm. Cardiovasc Ther 2021;2021:6615400.
764 765 766 767	24.	Summerhill VI, Sukhorukov VN, Eid AH, Nedosugova LV, Sobenin IA, Orekhov AN. Pathophysiological Aspects of the Development of Abdominal Aortic Aneurysm with a Special Focus on Mitochondrial Dysfunction and Genetic Associations. Biomolecular Concepts 2021;12:55–67.
768 769 770	25.	Chistiakov DA, Shkurat TP, Melnichenko AA, Grechko AV, Orekhov AN. The role of mitochondrial dysfunction in cardiovascular disease: a brief review. Annals of Medicine 2018;50:121–7.
771 772 773	26.	Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA, et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. American Journal of Physiology-Heart and Circulatory Physiology 2009;296:H1329–35.
774 775 776	27.	Shin SJ, Hang HT, Thang BQ, Shimoda T, Sakamoto H, Osaka M, et al. Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2020;40:1905–17.
777 778 779 780	28.	Wang S, Liu H, Yang P, Wang Z, Ye P, Xia J, et al. A role of inflammaging in aortic aneurysm: new insights from bioinformatics analysis. Frontiers in Immunology [Internet] 2023 [cited 2023 Dec 17];14. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1260688
781 782 783	29.	Sung PH, Yang YH, Chiang HJ, Chiang JY, Chen CJ, Liu CT, et al. Risk of aortic aneurysm and dissection in patients with autosomal-dominant polycystic kidney disease: a nationwide population-based cohort study. Oncotarget 2017;8:57594–604.
784 785	30.	Kugo H, Moriyama T, Zaima N. The role of perivascular adipose tissue in the appearance of ectopic adipocytes in the abdominal aortic aneurysmal wall. Adipocyte 2019;8:229–39.

786 787	31.	Chislock EM, Pendergast AM. Abl Family Kinases Regulate Endothelial Barrier Function In Vitro and in Mice. PLoS One 2013;8:e85231.
788 789 790	32.	Beghi S, Furmanik M, Jaminon A, Veltrop R, Rapp N, Wichapong K, et al. Calcium Signalling in Heart and Vessels: Role of Calmodulin and Downstream Calmodulin- Dependent Protein Kinases. Int J Mol Sci 2022;23:16139.
791 792 793	33.	Bround MJ, Wambolt R, Luciani DS, Kulpa JE, Rodrigues B, Brownsey RW, et al. Cardiomyocyte ATP Production, Metabolic Flexibility, and Survival Require Calcium Flux through Cardiac Ryanodine Receptors in Vivo. J Biol Chem 2013;288:18975–86.
794 795 796	34.	Colotti G, Poser E, Fiorillo A, Genovese I, Chiarini V, Ilari A. Sorcin, a Calcium Binding Protein Involved in the Multidrug Resistance Mechanisms in Cancer Cells. Molecules 2014;19:13976–89.
797 798	35.	Sanders KM. Invited Review: Mechanisms of calcium handling in smooth muscles. Journal of Applied Physiology 2001;91:1438–49.
799 800	36.	Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental Hematology & Oncology 2012;1:36.
801 802	37.	Zhang L, Wang Y. B lymphocytes in abdominal aortic aneurysms. Atherosclerosis 2015;242:311–7.
803 804	38.	Forester ND, Cruickshank SM, Scott DJA, Carding SR. Functional characterization of T cells in abdominal aortic aneurysms. Immunology 2005;115:262–70.
805 806 807 808 809	39.	Sagan A, Mikolajczyk TP, Mrowiecki W, MacRitchie N, Daly K, Meldrum A, et al. T Cells Are Dominant Population in Human Abdominal Aortic Aneurysms and Their Infiltration in the Perivascular Tissue Correlates With Disease Severity. Frontiers in Immunology [Internet] 2019 [cited 2024 Feb 9];10. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01979
810 811 812	40.	Xiong T, Lv XS, Wu GJ, Guo YX, Liu C, Hou FX, et al. Single-Cell Sequencing Analysis and Multiple Machine Learning Methods Identified G0S2 and HPSE as Novel Biomarkers for Abdominal Aortic Aneurysm. Front Immunol 2022;13:907309.
813 814 815	41.	Ferreira PG, Muñoz-Aguirre M, Reverter F, Sá Godinho CP, Sousa A, Amadoz A, et al. The effects of death and post-mortem cold ischemia on human tissue transcriptomes. Nat Commun 2018;9:490.
816 817	42.	Forester ND, Cruickshank SM, Scott DJA, Carding SR. Increased natural killer cell activity in patients with an abdominal aortic aneurysm. British Journal of Surgery 2006;93:46–54.
818 819 820	43.	Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, et al. Association Between Osteopontin and Human Abdominal Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology 2007;27:655–60.
821 822 823	44.	Black KM, Masuzawa A, Hagberg RC, Khabbaz KR, Trovato ME, Rettagliati VM, et al. Preliminary Biomarkers for Identification of Human Ascending Thoracic Aortic Aneurysm. J Am Heart Assoc 2013;2:e000138.

824 825	45.	Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clinical Biochemistry 2018;59:17–24.
826 827 828	46.	Wang SK, Green LA, Gutwein AR, Gupta AK, Babbey CM, Motaganahalli RL, et al. Osteopontin may be a driver of abdominal aortic aneurysm formation. Journal of Vascular Surgery 2018;68:22S-29S.
829 830 831 832	47.	Liu H, Zhang Y, Song W, Sun Y, Jiang Y. Osteopontin N-Terminal Function in an Abdominal Aortic Aneurysm From Apolipoprotein E-Deficient Mice. Frontiers in Cell and Developmental Biology [Internet] 2021 [cited 2023 Nov 22];9. Available from: https://www.frontiersin.org/articles/10.3389/fcell.2021.681790
833 834 835	48.	Qin X, He L, Tian M, Hu P, Yang J, Lu H, et al. Smooth muscle-specific Gsα deletion exaggerates angiotensin II-induced abdominal aortic aneurysm formation in mice in vivo. J Mol Cell Cardiol 2019;132:49–59.
836 837 838	49.	Zhang R, Ji Z, Yao Y, Zuo W, Yang M, Qu Y, et al. Identification of hub genes in unstable atherosclerotic plaque by conjoint analysis of bioinformatics. Life Sciences 2020;262:118517.
839 840	50.	Greene D, Pirri D, Frudd K, Sackey E, Al-Owain M, Giese APJ, et al. Genetic association analysis of 77,539 genomes reveals rare disease etiologies. Nat Med 2023;29:679–88.
841 842 843	51.	Kobeissi E, Hibino M, Pan H, Aune D. Blood pressure, hypertension and the risk of abdominal aortic aneurysms: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2019;34:547–55.
844 845	52.	Wang B, Cai W, Ai D, Zhang X, Yao L. The Role of Deubiquitinases in Vascular Diseases. J. of Cardiovasc. Trans. Res. 2020;13:131–41.
846 847	53.	Johnson M. Molecular mechanisms of β 2-adrenergic receptor function, response, and regulation. Journal of Allergy and Clinical Immunology 2006;117:18–24.
848 849 850	54.	Ding T, Zhou Y, Long R, Chen C, Zhao J, Cui P, et al. DUSP8 phosphatase: structure, functions, expression regulation and the role in human diseases. Cell & Bioscience 2019;9:70.
851 852 853	55.	Baldo G, Wu S, Howe RA, Ramamoothy M, Knutsen RH, Fang J, et al. Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol Genet Metab 2011;104:608–19.
854 855	56.	Emery P, Durand B, Mach B, Reith W. RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom. Nucleic Acids Res 1996;24:803–7.
856 857 858	57.	Liu Y, Wang X, Wang H, Hu T. Identification of key genes and pathways in abdominal aortic aneurysm by integrated bioinformatics analysis. J Int Med Res 2020;48:0300060519894437.
859 860 861	58.	Du P, Gao K, Cao Y, Yang S, Wang Y, Guo R, et al. RFX1 downregulation contributes to TLR4 overexpression in CD14+ monocytes via epigenetic mechanisms in coronary artery disease. Clin Epigenetics 2019;11:44.

862 863 864	59.	Blomkalns AL, Gavrila D, Thomas M, Neltner BS, Blanco VM, Benjamin SB, et al. CD14 Directs Adventitial Macrophage Precursor Recruitment: Role in Early Abdominal Aortic Aneurysm Formation. J Am Heart Assoc 2013;2:e000065.
865 866 867	60.	An imprinted, mammalian bicistronic transcript encodes two independent proteins PNAS [Internet]. [cited 2024 Feb 12];Available from: https://www.pnas.org/doi/10.1073/pnas.96.10.5616
868 869	61.	Zhang K, Li M, Yin L, Fu G, Liu Z. Role of thrombospondin-1 and thrombospondin-2 in cardiovascular diseases (Review). Int J Mol Med 2020;45:1275–93.
870 871 872 873	62.	Liu Z, Morgan S, Ren J, Wang Q, Annis DS, Mosher DF, et al. Thrombospondin-1 (TSP1) Contributes to the Development of Vascular Inflammation by Regulating Monocytic Cell Motility in Mouse Models of Abdominal Aortic Aneurysm. Circulation Research 2015;117:129–41.
874 875 876	63.	Wang C, Gong B, Bushel PR, Thierry-Mieg J, Thierry-Mieg D, Xu J, et al. A comprehensive study design reveals treatment- and transcript abundance–dependent concordance between RNA-seq and microarray data. Nat Biotechnol 2014;32:926–32.
877 878	64.	Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15–21.
879 880	65.	Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011;12:323.
881 882 883	66.	Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res 2012;22:1760–74.
884 885 886	67.	Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological) 1995;57:289–300.
887 888	68.	Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. OMICS 2012;16:284–7.
889 890 891 892	69.	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences 2005;102:15545– 50.
893 894 895	70.	KEGG: new perspectives on genomes, pathways, diseases and drugs Nucleic Acids Research Oxford Academic [Internet]. [cited 2023 Apr 27];Available from: https://academic.oup.com/nar/article/45/D1/D353/2605697
896 897	71.	Storey JD. A Direct Approach to False Discovery Rates. Journal of the Royal Statistical Society. Series B (Statistical Methodology) 2002;64:479–98.
898 899	72.	Kerseviciute I, Gordevicius J. aPEAR: an R package for autonomous visualization of pathway enrichment networks. Bioinformatics 2023;39:btad672.

900 901	73.	Yu G, Hu E, Gao CH. enrichplot: Visualization of Functional Enrichment Result [Internet]. 2023 [cited 2023 Nov 21];Available from: https://bioconductor.org/packages/enrichplot/
902 903	74.	Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 2018;1711:243–59.
904 905	75.	Castel SE, Mohammadi P, Chung WK, Shen Y, Lappalainen T. Rare variant phasing and haplotypic expression from RNA sequencing with phASER. Nat Commun 2016;7:12817.
906 907 908	76.	Degner JF, Marioni JC, Pai AA, Pickrell JK, Nkadori E, Gilad Y, et al. Effect of read-mapping biases on detecting allele-specific expression from RNA-sequencing data. Bioinformatics 2009;25:3207–12.
909 910	77.	van de Geijn B, McVicker G, Gilad Y, Pritchard JK. WASP: allele-specific software for robust molecular quantitative trait locus discovery. Nat Methods 2015;12:1061–3.
911 912	78.	Castel SE, Aguet F, Mohammadi P, Aguet F, Anand S, Ardlie KG, et al. A vast resource of allelic expression data spanning human tissues. Genome Biology 2020;21:234.
913 914 915	79.	van Beek D, Verdonschot J, Derks K, Brunner H, de Kok TM, Arts ICW, et al. Allele-specific expression analysis for complex genetic phenotypes applied to a unique dilated cardiomyopathy cohort. Sci Rep 2023;13:564.

- 916 **FIGURE LEGENDS**
- 917 Figure 1
- 918 Study design flowchart.
- 919 Figure 2
- 920 Hierarchical clustering analysis results with all the DEGs between AAA and controls (A) and
- 921 after removing DEG by ischemic time (B). C) Comparison of the proportion of inflammatory
- 922 cells between AAA and controls using CIBERSORTx.
- 923 Figure 3
- A) Significant alternative splicing types identified between AAA and controls. B) Venn diagram
- 925 showing the overlap between DEGs in AAA and controls and genes with differential alternative
- 926 splicing patterns in AAA and controls. C) Venn diagram showing the overlap between DEGs in
- 927 AAA and controls and DEGs by AAA diameter.
- 928 Figure 4

- 929 A) Results of PC analysis clustering between AAA and controls. B) Hierarchical clustering
- 930 analysis results with genes with different allelic specific patterns between AAA and controls.

931 SUPPLEMENTARY INFORMATION

- 932 Additional file 1: Figures S1-S6
- 933 Contains Supplementary Figures S1-S6.
- 934 Additional file 2: Table S1
- 935 Complete differential expression results between AAA and controls.
- 936 Additional file 3: Table S2
- 937 GO functional enrichment analysis results between AAA and controls (including genes affected
- 938 by ischemic time).
- 939 Additional file 4: Table S3
- 940 KEGG functional enrichment analysis results between AAA and controls (including genes
- 941 affected by ischemic time).
- 942 Additional file 5: Table S4
- 943 Differential expressed genes by ischemic time in GTEx samples.
- 944 Additional file 6: Table S5
- 945 GO functional enrichment analysis results between AAA and controls (excluding genes affected
- 946 by ischemic time).
- 947 Additional file 7: Table S6
- 948 KEGG functional enrichment analysis results between AAA and controls (excluding genes
- 949 affected by ischemic time).

950 Additional file 8: Table S7

- 951 Results of the alternative splicing study between AAA and controls.
- 952 Additional file 9: Table S8
- 953 Complete differential expression results between AAA of different diameter.
- 954 Additional file 10: Table S9
- 955 Correlation analysis between biological and technical covariates.







C)









A)

B)